Literatur
- 1
Turaga K, Acs G, Laronga C.
Gene expression profiling in breast cancer.
Cancer Control.
2010;
17 (3)
177-82
- 2
Underhill C, Toulmonde M, Bonnefoi H.
A review of PARP inhibitors: from bench to bedside.
Ann Oncol.
2011;
22 (2)
268-79
- 3
Byrski T, et al.
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.
Breast Cancer Res Treat.
2009;
115 (2)
359-63
- 4
Minckwitz G von, et al.
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide
in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
J Natl Cancer Inst.
2008;
100 (8)
542-51
Korrespondierender Autor
Dr. Sarah Schott
Universitätsfrauenklinik Heidelberg
Nationales Centrum für Tumor-erkrankungen (NCT)
Voßstr. 9
69115 Heidelberg
eMail: sarah.schott@med.uni-heidelberg.de
